Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib (Q58767811)
Jump to navigation
Jump to search
scholarly article by Oliver Ottmann et al published 3 September 2018 in Blood Cancer Journal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
scholarly article by Oliver Ottmann et al published 3 September 2018 in Blood Cancer Journal |
Statements
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib (English)
0 references
3 September 2018
0 references
8
0 references
9
0 references
88
0 references
1 September 2018
1 reference